Common Contracts
23 similar Key Executive Severance Agreement contracts by Poniard Pharmaceuticals, Inc., Neorx Corp
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 11th, 2010 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Key Executive Severance Agreement (this “Agreement”), dated as of February 5, 2010, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and Michael S. Perry, DVM, Ph.D. (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and CHENI KWOK (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and ROBERT L. DE JAGER (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and JANET R. REA (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Key Executive Severance Agreement (this “Agreement”), dated as of February 18, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and Greg Weaver (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and RONALD A. MARTELL (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and ANNA WIGHT (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENT (CEO)Key Executive Severance Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10 hereof, the “Company”), and GERALD MCMAHON (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10, the “Company”), and RONALD MARTELL (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10, the “Company”), and CAROLINE LOEWY (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10, the “Company”), and GERALD MCMAHON (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10, the “Company”), and DAVID KARLIN (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Key Executive Severance Agreement (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 10, the “Company”), and ANNA WIGHT (the “Executive”).
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 11th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (this “Agreement”), dated as of February 1, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10, the “Company”), and Robert L. De Jager (the “Executive”).
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • August 9th, 2007 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of May 7, 2007, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10, the “Company”), and Ronald A. Martell (the “Executive”).
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2007 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of May 7, 2007, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10, the “Company”), and Ronald A. Martell (the “Executive”).
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENT (VP)Key Executive Severance Agreement • August 14th, 2006 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of July 24, 2006, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10, the “Company”), and Alan B. Glassberg, M.D. (the “Executive”).
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENT (VP)Key Executive Severance Agreement • June 23rd, 2006 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of July 1, 2006, is entered into by and between PONIARD PHARMACEUTICALS, INC. (formerly NeoRx Corporation), a Washington corporation (as supplemented by Section 10, the “Company”), and Cheni Kwok (the “Executive”).
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENT (VP)Key Executive Severance Agreement • June 23rd, 2006 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of June 23, 2006, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10, the “Company”), and Caroline M. Loewy (the “Executive”).
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • June 29th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), effective as of JUNE 23, 2005, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the “Company”), and David A. Karlin (the “Executive”).
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • October 19th, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of October 25, 2004, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the “Company”), and Susan D. Berland (the “Executive”).
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • August 9th, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of May 11, 2004, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the “Company”), and GERALD MCMAHON (the “Executive”).
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENT (VP)Key Executive Severance Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of , 20 , is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the “Company”), and (the “Executive”).
